FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2156834983> ?p ?o ?g. }

• W2156834983 endingPage "383" @default.
• W2156834983 startingPage "375" @default.
• W2156834983 abstract "Abstract Resistance to FLT3 inhibitors is a serious clinical issue in treating acute myelogenous leukemia (AML). AMG 925, a dual FLT3/CDK4 inhibitor, has been developed to overcome this resistance. It is hypothesized that the combined inhibition of FLT3 and CDK4 may reduce occurrence of the FLT3 resistance mutations, and thereby prolong clinical responses. To test this hypothesis, we attempted to isolate AML cell clones resistant to AMG 925 or to FLT3 inhibitors. After a selection of over 8 months with AMG 925, we could only isolate partially resistant clones. No new mutations in FLT3 were found, but a 2- to 3-fold increase in total FLT3 protein was detected and believed to contribute to the partial resistance. In contrast, selection with the FLT3 inhibitors sorafenib or AC220 (Quizartinib), led to a resistance and the appearance of a number of mutations in FLT3 kinase domains, including the known hot spot sites D835 and F691. However, when AC220 was combined with the CDK4 inhibitor PD0332991 (palbociclib) at 0.1 μmol/L or higher, no resistance mutations were obtained, indicating that the CDK4-inhibiting activity of AMG 925 contributed to the failure to develop drug resistance. AMG 925 was shown to potently inhibit the FLT3 inhibitor–resistant mutation D835Y/V. This feature of AMG 925 was also considered to contribute to the lack of resistance mutations to the compound. Together, our data suggest that AMG 925 has the potential to reduce resistance mutations in FLT3 and may prolong clinical responses. Mol Cancer Ther; 14(2); 375–83. ©2014 AACR." @default.
• W2156834983 created "2016-06-24" @default.
• W2156834983 creator A5000280003 @default.
• W2156834983 creator A5004127240 @default.
• W2156834983 creator A5005053576 @default.
• W2156834983 creator A5009590736 @default.
• W2156834983 creator A5021521707 @default.
• W2156834983 creator A5021736941 @default.
• W2156834983 creator A5045019377 @default.
• W2156834983 creator A5053252660 @default.
• W2156834983 creator A5076815798 @default.
• W2156834983 creator A5076971720 @default.
• W2156834983 creator A5078775033 @default.
• W2156834983 creator A5091212355 @default.
• W2156834983 date "2015-02-01" @default.
• W2156834983 modified "2023-10-14" @default.
• W2156834983 title "AMG 925 Is a Dual FLT3/CDK4 Inhibitor with the Potential to Overcome FLT3 Inhibitor Resistance in Acute Myeloid Leukemia" @default.
• W2156834983 cites W1495575342 @default.
• W2156834983 cites W1966170687 @default.
• W2156834983 cites W1973537479 @default.
• W2156834983 cites W1981844030 @default.
• W2156834983 cites W1984209370 @default.
• W2156834983 cites W1993300766 @default.
• W2156834983 cites W1996318954 @default.
• W2156834983 cites W1997073961 @default.
• W2156834983 cites W2009178790 @default.
• W2156834983 cites W2011187792 @default.
• W2156834983 cites W2012753533 @default.
• W2156834983 cites W2016883830 @default.
• W2156834983 cites W2017060505 @default.
• W2156834983 cites W2017107901 @default.
• W2156834983 cites W2035273416 @default.
• W2156834983 cites W2041027929 @default.
• W2156834983 cites W2048369203 @default.
• W2156834983 cites W2050768356 @default.
• W2156834983 cites W2051724614 @default.
• W2156834983 cites W2055061133 @default.
• W2156834983 cites W2056465113 @default.
• W2156834983 cites W2057274133 @default.
• W2156834983 cites W2059671636 @default.
• W2156834983 cites W2063981273 @default.
• W2156834983 cites W2078136694 @default.
• W2156834983 cites W2080732293 @default.
• W2156834983 cites W2083221109 @default.
• W2156834983 cites W2085066928 @default.
• W2156834983 cites W2088757697 @default.
• W2156834983 cites W2092815384 @default.
• W2156834983 cites W2103201873 @default.
• W2156834983 cites W2106198179 @default.
• W2156834983 cites W2113230030 @default.
• W2156834983 cites W2129615499 @default.
• W2156834983 cites W2131138683 @default.
• W2156834983 cites W2135338251 @default.
• W2156834983 cites W2149139293 @default.
• W2156834983 cites W2152616419 @default.
• W2156834983 cites W2154625299 @default.
• W2156834983 cites W2155609574 @default.
• W2156834983 cites W2155715347 @default.
• W2156834983 cites W2166465642 @default.
• W2156834983 doi "https://doi.org/10.1158/1535-7163.mct-14-0388" @default.
• W2156834983 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25487917" @default.
• W2156834983 hasPublicationYear "2015" @default.
• W2156834983 type Work @default.
• W2156834983 sameAs 2156834983 @default.
• W2156834983 citedByCount "25" @default.
• W2156834983 countsByYear W21568349832015 @default.
• W2156834983 countsByYear W21568349832016 @default.
• W2156834983 countsByYear W21568349832017 @default.
• W2156834983 countsByYear W21568349832018 @default.
• W2156834983 countsByYear W21568349832019 @default.
• W2156834983 countsByYear W21568349832020 @default.
• W2156834983 countsByYear W21568349832021 @default.
• W2156834983 countsByYear W21568349832022 @default.
• W2156834983 countsByYear W21568349832023 @default.
• W2156834983 crossrefType "journal-article" @default.
• W2156834983 hasAuthorship W2156834983A5000280003 @default.
• W2156834983 hasAuthorship W2156834983A5004127240 @default.
• W2156834983 hasAuthorship W2156834983A5005053576 @default.
• W2156834983 hasAuthorship W2156834983A5009590736 @default.
• W2156834983 hasAuthorship W2156834983A5021521707 @default.
• W2156834983 hasAuthorship W2156834983A5021736941 @default.
• W2156834983 hasAuthorship W2156834983A5045019377 @default.
• W2156834983 hasAuthorship W2156834983A5053252660 @default.
• W2156834983 hasAuthorship W2156834983A5076815798 @default.
• W2156834983 hasAuthorship W2156834983A5076971720 @default.
• W2156834983 hasAuthorship W2156834983A5078775033 @default.
• W2156834983 hasAuthorship W2156834983A5091212355 @default.
• W2156834983 hasBestOaLocation W21568349831 @default.
• W2156834983 hasConcept C104317684 @default.
• W2156834983 hasConcept C114851261 @default.
• W2156834983 hasConcept C121608353 @default.
• W2156834983 hasConcept C185592680 @default.
• W2156834983 hasConcept C2775930923 @default.
• W2156834983 hasConcept C2778019345 @default.
• W2156834983 hasConcept C2778695046 @default.
• W2156834983 hasConcept C2778729363 @default.
• W2156834983 hasConcept C2779744173 @default.
• W2156834983 hasConcept C2910954276 @default.

• next